Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study
Author:
Publisher
Wiley
Subject
Infectious Diseases,Dermatology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdv.12046/fullpdf
Reference17 articles.
1. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL;Gordon;J Am Acad Dermatol,2012
2. Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years;Kimball;Br J Dermatol,2012
3. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1);Leonardi;Lancet,2008
4. Severe psoriasis - oral therapy with a new retinoid;Fredriksson;Dermatologica,1978
5. Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use;Finlay;Clin Exp Dermatol,1994
Cited by 171 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Association between several immune response‐related genes and the effectiveness of biological treatments in patients with moderate‐to‐severe psoriasis;Experimental Dermatology;2024-01
2. Risk of Major Adverse Cardiovascular Events in Immune-Mediated Inflammatory Disorders on Biologics and Small Molecules: Network Meta-Analysis;Clinical Gastroenterology and Hepatology;2023-10
3. The selection of the initial drug in the treatment of severe psoriasis;Meditsinskiy sovet = Medical Council;2023-09-27
4. Effectiveness, safety and quality‐of‐life effects of guselkumab and ustekinumab in patients with psoriasis: Week 104 results from the non‐interventional, prospective, German multicentre PERSIST study;Journal of the European Academy of Dermatology and Venereology;2023-07-18
5. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis;Cochrane Database of Systematic Reviews;2023-07-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3